Navigation Links
Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
Date:2/2/2009

TSX Venture: QPT

EDMONTON, Feb. 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, announces that it has entered into an agreement with Loewen, Ondaatje, McCutcheon Limited ("LOM") to provide financial advisory services in connection with various business development opportunities.

"The current capital market conditions have provided us with alternative strategic opportunities including mergers and acquisitions, strategic partnerships and monetizing certain capital assets," said Dr. Madiyalakan, Chief Executive Officer for Quest. "In order to position the Company for future growth and to increase shareholder value, we are evaluating these alternatives with the help of LOM." In addition, Quest would also like to leverage the valuable clinical and preclinical data it has generated from its proprietary SonoLight Technology, as well as the continuing support from its current shareholders.

Quest also announces the grant of 300,000 stock options to its three independent board members at an exercise price of $0.15. All allocations will be subject to approval of the TSX Venture Exchange.

Quest has four product candidates in development based on its proprietary SonoLight Technology. SL017, for hair removal, is currently in a Phase II, 110-patient clinical trial. SL017, for the treatment of actinic keratosis, has been shown to be safe and well tolerated in a Phase 1 dose-escalation clinical trial. SL017, for the treatment of acne, has completed evaluation in a Phase 1 clinical trial. SL052, which is being developed to treat prostate cancer, has completed preclinical studies.

About Quest PharmaTech Inc. Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It i
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Ambassador to Speak at E...Toronto, Canada (Vocus) November 25, 2009 -- Ambas... ,Who: ,David Appia, French Ambassador for Interna...est in France Agency ,To view a biography of David... ,Ambassador Appia is available to meet with press...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...o 2013 ,, http://www.reportlinker.com/p016550...to-2013.html ,, Brazil Bioethanol Market Analy...e report provides detailed analysis and forecasts ...
(Date:11/24/2009)... Ambassador to also Visit...er 24, 2009 -- , , ,Who: David Appia, French Ambas...nd CEO of the Invest in France Agency, , , , ,Wha...s to discuss recent pro-business initiatives adopt...cal and academic landscape for innovation and deve...
(Date:11/24/2009)..., , REYKJAVIK, Iceland, N...cs, Inc. (Nasdaq: DCGN ) today announced that it h...at trading in the company,s common stock will be,s... will be filed with the,Securities and Exchange Co...from listing on Nasdaq, unless the company files a...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
..., , The BioRobot MDx is the latest addition...d is designed to meet the needs , of scient...nts such as clinical , testing laboratories... Benefits of the BioRobot MDx: , , ...tion and reaction setup - proven , QIAa...
... , Part V: Counting cells , , ...oviding useful hints for , culturing animal...ounting , cells. , , This pr...ols in this , series are examples of method... rigorously validated and optimized by QIAGEN. ...
... , , , Scott Tarpinian , Ep... , , , , , , Introductio... in molecular biology research, providing , ...uch as genome analysis, , sequencing, and...tandard , PCR conditions, amplification o...
Other Biology Technology:BioRobot MDx standardize your automated protocols in clinical , laboratories 2BioRobot MDx standardize your automated protocols in clinical , laboratories 3BioRobot MDx standardize your automated protocols in clinical , laboratories 4BioRobot MDx standardize your automated protocols in clinical , laboratories 5The QIAGEN Guide to Animal Cell Culture 2The QIAGEN Guide to Animal Cell Culture 3TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 2TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 3TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 4TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 5TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 6TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 7TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 8TripleMaster PCR SystemThe Ideal Choice for Long-Range PCR 9
(Date:11/30/2009)...lorless and odorless radioactive gas that is produ...a product of uranium decay and is found in trace a...roundwater as well as building materials, plants, ...ion is expressed as the amount of radiation that w... a liter of air; thus the units are picocuries per...
(Date:11/26/2009)...d out in eight European countries has shown that c...se pandemic could have a significant role in reduc...he open access journal BMC Infectious Diseases c... and weekends/holidays, finding that they were red...sselt and Antwerp University, Belgium, led a team ...
(Date:11/25/2009)....Scientists at the California Institute of Technol...ve emotion-like behavior in the fruit fly, Drosop...be relevant to the relationship between the neurot...ivity disorder (ADHD), are described in the Decemb...ila brain contains only about 20,000 neurons and ...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2School closure could reduce swine flu transmission by 21 percent 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Expanding Health Coverage May Not Improve Access 53940 1Expanding Health Coverage May Not Improve Access 53940 2Expanding Health Coverage May Not Improve Access 53940 3SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 1SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 2SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 3SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 4SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 5SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 6SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 7SCOLR Pharma Inc Reports Second Quarter 2009 Financial Results 13451 8EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 1EGEN Inc Announces the Promotion of Jason Fewell Ph D to Vice President of Preclinical Research and Development 13448 2
... A range of complex surgical operations necessary...es or address blockages in the bloodstream are abo...Nanophysics Research Laboratory at Australia,s Mon... of micro-motors small enough to be injected into ...ished today, Tuesday, 20 January, in IOP Publishin...
... EDITOR,S PICK: Fetal heath affected by mother,s...ecent dramatic rise in the number of children clas... diseases, such as type 2 diabetes and nonalcoholi...to contribute to this rise is obesity of the mothe..., at Oregon Health and Science University, Beavert...
... , In terms of diversity and sheer numbers, the mi...llions of people inhabiting the Earth. Numbering i...sands of distinct genetic families, this microbiom...y of regulatory and digestive functions, many stil... may be linked to body weight changes associated w...
Other Biology News:Microbot motors fit to swim human arteries 2JCI online early table of contents: Jan. 19, 2009 2JCI online early table of contents: Jan. 19, 2009 3JCI online early table of contents: Jan. 19, 2009 4Our microbes, ourselves 2Our microbes, ourselves 3Our microbes, ourselves 4
Cytological Nuclear Counterstain Kit - DAPI/SYTOX Green/PI - 300 slides from Molecular Probes (Invitrogen)
Goat Anti-Human SorCS1 Polyclonal Antibody, Unconjugated from R&D Systems
Goat Anti-Human PLUNC Polyclonal Antibody, Biotin Conjugated from R&D Systems
Mouse Anti-Human RXR beta / NR2B2 Monoclonal Antibody, Unconjugated, Clone H7341 from R&D Systems
Biology Products: